The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

NCT02627820 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: Isis 420915/GSK 299872

Sponsor

Brigham and Women's Hospital

Collaborators

[object Object]
[object Object]